A carregar...
Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease
Taliglucerase alfa is an intravenous enzyme replacement therapy approved for treatment of type 1 Gaucher disease (GD), and is the first available plant cell–expressed recombinant therapeutic protein. Herein, we report long‐term safety and efficacy results of taliglucerase alfa in treatment‐naïve adu...
Na minha lista:
Publicado no: | Am J Hematol |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
John Wiley and Sons Inc.
2016
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5074246/ https://ncbi.nlm.nih.gov/pubmed/27174694 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24369 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|